Allosteric Hemoglobin Modulators for Sickle Cell Oxygenation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutics are inadequate for effectively treating disorders mediated by sickle hemoglobin (HbS), which leads to oxygen deficiency and tissue damage due to the rigid, sickle-shaped red blood cells in sickle cell disease.
Innovation Solution
Development of compounds and pharmaceutical compositions that act as allosteric modulators of hemoglobin, specifically increasing oxygen affinity in hemoglobin S, thereby addressing the underlying cause of oxygen deficiency in sickle cell anemia.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If allosteric modulators are used to increase oxygen affinity of hemoglobin S, then oxygen deficiency is alleviated, but the complexity of the therapeutic solution increases
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of hemoglobin through allosteric modulation. The compounds change the conformational state of hemoglobin, shifting the oxygen dissociation curve to increase oxygen affinity. This resolves the contradiction by using chemical parameter modification rather than complex device-based solutions to improve oxygen delivery reliability.
Solution Approach 2:
The allosteric modulator compounds act as intermediaries between the therapeutic goal and the hemoglobin target. These small molecule compounds bind to specific allosteric sites on hemoglobin, mediating the effect of increasing oxygen affinity without requiring direct genetic modification or complex delivery systems. This intermediary approach simplifies the overall therapeutic strategy while achieving reliable oxygen delivery improvement.
2Reliability
If compounds are developed to treat sickle cell disease, then patient outcomes improve, but the time and resources required for development increase
Solution Approach 1:
The patent employs preliminary action by designing compounds with predetermined allosteric binding characteristics before clinical application. The chemical structures are pre-optimized to ensure specific binding to hemoglobin allosteric sites, allowing the compounds to immediately exert their oxygen-affinity-enhancing effect upon administration. This pre-engineering of molecular function reduces development time while maintaining treatment effectiveness.
Solution Approach 2:
By focusing on parameter changes in hemoglobin's oxygen-binding characteristics rather than attempting to correct the underlying genetic mutation, the patent accelerates development. The allosteric modulators directly modify the functional parameters of hemoglobin (oxygen affinity, cooperativity) without requiring long-term genetic therapy development, thus improving treatment effectiveness more rapidly.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The proposed compounds enhance oxygen affinity of hemoglobin S, potentially alleviating symptoms of sickle cell disease by improving tissue and cellular oxygenation, thereby treating oxygen deficiency associated with the condition.
Implementation Method 1
compounds and pharmaceutical compositions suitable as allosteric modulators of hemoglobin
Implementation Method 2
Hemoglobin binds and releases oxygen through conformational changes
Data Source
AI summary
Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.